Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > It will take years to go through human trials and they

<< Previous

Bullboard Posts

Next >>

Comment by losermeon Mar 13, 2021 10:49am

210 Views

Post# 32792647

RE:It will take years to go through human trials and they

You are not paying attention!!!! Fast- track here because of COVID. For examples
Instead of a two years course to get your diploma, a fast- tracked program only takes less than a six months to complete and you still get a diploma after graduation.

Summer courses only take a month to complete instead of a whole semester to save time and money.

Same concept here with KLY and other COVID related products and vaccines

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3